SytriDK2
SytriDK2
Based on polymethoxylated flavones, tocotrienols, microencapsulated vitamin K2 and vegan vitamin D3 from Lichen.
Properties
One of the risk factors in modern nutrition is represented by the excess of saturated fats and simple sugars and the lack of fiber and antioxidants, which combined with the high systemic inflammatory level that can arise from incorrect lifestyles, can favor an accumulation of cholesterol at the endothelial level with oxidation of LDL and extraosseous calcium deposition, the first step for the formation of atherosclerotic plaques. A balanced diet and the use of specific supplements can help to correctly transport calcium into the bones, to keep plasma levels of cholesterol, triglycerides and the systemic inflammatory level under control, for the overall well-being of the cardiovascular system and bone tissue.
SytriDK2 contains the unique synergy of vitamin D3 (cholecalciferol), the active form of vitamin D, and vitamin K2 (menaquinone-7), with tocotrienols and flavonoids from citrus nobilis with antioxidant and anti-inflammatory action and control of plasma lipid levels. The synergy between vitamin D3 and K2 is widely demonstrated: vitamin D3 promotes correct absorption of calcium and promotes the production of proteins that require vitamin K2 to function properly.
SytriDK2 works on both the osteoarticular system and the cardiovascular system. Vitamin D3 helps absorb calcium which, in the absence of vitamin K2 and magnesium, tends to deposit causing coronary calcifications that are a prelude to atherosclerosis.
Vitamin K2 promotes the fixation of calcium in bones and teeth, reducing the risk of fractures, improving density and level of bone mineralization in conditions such as osteopenia or osteoporosis, which occur especially with aging in conjunction with hormonal changes characteristic of menopause for example and with alterations in metabolism (metabolic syndrome, type 2 diabetes).
Physiological effects
Supports the health of the musculoskeletal and cardiovascular systems.
Ingredients
- Citrus nobilis dry extract tit. 40% in polymethoxylated flavones (PMF)
- Tocotrienols from palm
- Vitamin K2 VITAL® DELTA (Menaquinone-7)
- Vitamin D3 (cholecalciferol) vegan from lichen
- Anti-caking agents: corn starch, gum arabic, calcium carbonate, silicon dioxide, vegetable magnesium stearate
- Acid-resistant vegetable capsules DRcapsTM
| Average content of characterizing ingredients | per daily doses (1 capsule) | RDA |
| Citrus nobilis dry extract tit. 40% | 286 mg | |
| PMF content | 114,5 mg | |
| Tocotrienols | 12 mg | |
| Vitamin K2 (Menaquinone-7) | 100 mcg | |
| Vitamin D3 (Cholecalciferol) | 50 mcg (2.000 U.I.) | |
| Rosa canina dry extract | 90 mg | |
| Vitamin C content |
63 mg | 78 % |
| Methylsulfonylmethane (MSM) | 30 mg | |
| Chromium | 200 mcg | 500% |
Instructions for use
1 capsule per day, to be taken with water
Format
30 capsules in blister pack
Notes
Listed in the register of supplements: code 135611
EAN Code: 8059173431069
Paraf Code: 981505201
Bibliography
- Borradaile NM, Carrol KK; Kurowska EM. Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperitin and naringenin. Lipids. 1999;34(6):591-598
- Kurowska EM, Manthey JA, Hasegawa S, Manners GD, Vanderberg TA. Cholesterol-lowering effects of citrus juices, flavonoids and limonoids. Paper presented at: International Conference and Exhibition on Nutraceuticals and Functional foods; September 13-17,2000; Houston, TX.
- Kullo IJ, Gau GT, Tajik Aj. Novel risk factors for atherosclerosis. Mayo CLin Proc. 2000; 75(4): 369-380.
- Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression or 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol Chem. 1993; 268(15): 11230-11238.
- Guthrie N, Kurowska EM. Anticancer and cholesterol-lowering activities of tocotrienols. In: Widman REC, ed. Handbook of Nutraceuticals and Functional Food. Boca Raton, FL: CRC Press; 2000:269-280.
- Quereshi AA, Bradlow BA, Brace L rt al.Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids 1995; 30(12):1171-1177.
- Schurgers LJ, Vermeer C.- Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis 2000;30:298-307.
- Abedin M, Tintut Y, Demer LL. ascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 2004; 24: 1161-70
- Saito E, Wachi H, Sato F, Sugitani H, Seyama Y. Treatment with vitamin K2 combined with bisphosphonates synergistically inhibits calcification in cultured smooth muscle cells. J Atheroscler Thromb 2007; 14:317-24
- Joline W.J. Beulens, Michiel L. Bots, Femke Atsma, Marie-Louise E.L. Bartelink et al.– “High dietary menaquinone intake is associated with reduced coronary calcification” – Apr. 2008
- Geleijnse JM, Vermeer C, Grobbee DE, Schurgers LJ, Knapen MH, van der Meer IM, Hofman A, Witteman JC. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J Nutr. 2004;134(11):3100-5.
- Beulens et al: High dietary menaquinone intake is associated with reduced coronary calcification. Atherosclerosis. 2008 Jul 19. 25. Beulens JW, Bots ML, Atsma F, Bartelink ML, Prokop M, Geleijnse JM, Witteman JC
Benefits
Supports the health of the musculoskeletal and cardiovascular systems.
In-house production cycle
We produce our supplements in our in-house laboratories to ensure performance and safety.
Useful product codes
Listed in the register of supplements: code 135611
EAN Code: 8059173431069
Paraf Code: 981505201
Reviews